Alexander Paris, an analyst from Barrington, reiterated the Buy rating on Healthequity. The associated price target is $110.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Alexander Paris has given his Buy rating due to a combination of factors tied to HealthEquity’s strong operational and financial execution. The company’s latest quarter exceeded expectations across revenue, adjusted EBITDA, and non-GAAP earnings per share, demonstrating robust operating leverage and profitability momentum.
He also points to management’s raised fiscal 2027 outlook for revenue, margins, and earnings as evidence of durable growth driven by new account wins and higher asset levels. In addition, he believes the firm’s leading position in the HSA market and favorable cash yield dynamics should support continued top-line expansion and margin improvement, while the current valuation still offers substantial upside to his $110 price target.
Paris covers the Consumer Defensive sector, focusing on stocks such as Covista, Perdoceo Education, and Stride. According to TipRanks, Paris has an average return of 16.9% and a 62.73% success rate on recommended stocks.